Revenue Breakdown
Composition ()
No data
Revenue Streams
Spero Therapeutics Inc (SPRO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Collaboration Revenue Related Party, accounting for 83.2% of total sales, equivalent to $11.80M. Another important revenue stream is Grant Revenue. Understanding this composition is critical for investors evaluating how SPRO navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Spero Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -134.67%, while the net margin is -135.65%. These profitability ratios, combined with a Return on Equity (ROE) of -95.29%, provide a clear picture of how effectively SPRO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SPRO competes directly with industry leaders such as ONCY and AGEN. With a market capitalization of $123.38M, it holds a leading position in the sector. When comparing efficiency, SPRO's gross margin of 100.00% stands against ONCY's N/A and AGEN's 97.88%. Such benchmarking helps identify whether Spero Therapeutics Inc is trading at a premium or discount relative to its financial performance.
